Serum Institute of India, Ltd.
Off Soli Poonawalla Road
31 articles with Serum Institute of India, Ltd.
The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.
The WHO’s Emergency Use Listing (EUL), a prerequisite for COVAX Facility vaccine supply, evaluates the safety, quality, and efficacy of the COVID-19 vaccines. As such, today’s approval allows the vaccine to be used by agencies and NGOs around the world.
Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018
- Tdap vaccine adjuvanted with CpG 1018 is focused on addressing rising incidence of pertussis since the change to acellular vaccines in the 1990s - CpG 1018 adjuvant has the potential to increase durability of the immune responses to pertussis and reduce transmission in previously vaccinated asymptomatic individuals
Serum Institute Of India And Dynavax Announce First Participants Dosed In The Phase 1/2 Clinical Trial For A COVID-19 Vaccine
Further strengthening its fight against COVID-19, Serum Institute of India (SIIPL), the world's largest vaccine manufacturer by volume, has partnered with Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing and commercializing novel vaccines, and today joint
ABEC , a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is supporting Serum Institute of India Pvt. Ltd. (SIIPL) in Pune, India by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine can
9/30/2020The Serum Institute of India (SII) has agreed to produce and deliver up to an additional 100 million doses of an approved COVID-19 vaccine for citizens of India and neighboring low- and middle-income countries as part of a collaboration with Gavi and the Bill & Melinda Gates Foundation.
Serum Institute of India Initiates Manufacturing of Codagenix's Intranasal Live-Attenuated COVID-19 Vaccine Candidate
- Phase 1 clinical trial of CDX-005 expected to initiate prior to year-end 2020 - Serum Institute to ramp-up manufacturing for large-scale safety and efficacy studies and to meet global vaccine supply requirements [22-September-2020] FARMINGDALE, N.Y. , Sept. 22, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing pr
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.
Novavax and Serum Institute of India Private Limited (SIIPL) amended an agreement struck last month that will allow the company to double the number of doses of its experimental COVID-19 vaccine for potential use in 2021.
Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
Novavax, Inc. announced an amendment to its existing agreement with Serum Institute of India Private Limited under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate.
SpyBiotech and Serum Institute of India announce that the first subjects have been dosed in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19
SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, announces that its partner the Serum Institute of India has dosed the first subjects in a Phase I/II trial of a novel virus-like particle vaccine targeting COVID-19.
Expected to support minimum of 1 billion doses of NVX-CoV2373 for India and low- and middle-income countries
Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University Phase 2b clinical efficacy study
Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19
FARMINGDALE, N.Y. , Feb. 13, 2020 /PRNewswire/ -- Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. There are no licensed vaccines or therapeutics for this nov
Aragen Bioscience, Inc and Serum Institute of India Pvt. Ltd. are pleased to announce a collaboration for the development of multiple stable cell lines to support Serum’s HIV program.
Aridis Pharmaceuticals Executes License Agreement with The Serum Institute of India, Ltd. for Exclusive Rights to Products and Utilization of MabIgX® Platform Technology
Aridis Pharmaceuticals, Inc. announced that it has consummated a licensing agreement with Serum AMR, an affiliate of Serum International BV and the Serum Institute of India, Ltd.
Aridis Pharmaceuticals Enters Into Equity Purchase and Option Agreements with The Serum Institute of India, Ltd for Exclusive License to Products and MabIgX® Platform Technology
Aridis Pharmaceuticals, Inc. announced that it has entered into an option agreement with the Serum International BV, an affiliate of Serum Institute of India, Ltd., the world's largest vaccine manufacturer by dose units.
Ascenion GmbH, the technology transfer partner of the Helmholtz Institute for Infection Research (HZI), has successfully negotiated the trade sale of the HZI spin-off Vakzine Projekt Management GmbH (VPM) to its longstanding partner, Serum Institute of India Pvt. Ltd (SII), in an all-cash deal.
Under the collaboration, SII is entitled to manufacture and sell fully liquid wP and Salk based IPV based Hexavalent vaccine developed and commercialized by PBL.